Authors: Westeel, Virginie; Quoix, Elisabeth; Baudrin, Laurence; Milleron, Bernard

Source: Aging Health, Volume 8, Number 2, April 2012 , pp. 119-122(4)

Publisher: Future Medicine

Abstract:

<bold>Evaluation of: Jalal SI, Riggs HD, Melnyk A et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a Phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann. Oncol. doi:10.1093/annonc/mdr565 (2011) (Epub ahead of print).</bold> The paper by Jalal et al. reports updated survival of a Phase III trial of concurrent chemoradiation with or without consolidation docetaxel for locally advanced non-small-cell lung cancer, and efficacy and tolerability data in patients ≥70 years. Of the 243 enrolled patients, 166 were randomized and 64 were aged ≥70 years (26%). There was no benefit of consolidation docetaxel. Median and 3-year survival was 17.1 months and 21.8% in patients ≥70 years, and 22.8 months and 34% in patients <70 years, respectively (p = 0.15). There were significantly more grade 3-4 toxicities (87 vs 73%; p = 0.02) and more hospitalizations in elderly patients (45 vs 32%; p = 0.03), but no increase in toxic deaths. Concurrent chemoradiation can be an option in elderly patients. However, significantly higher toxicity should be taken into account and elderly patients highly selected.

Keywords: cisplatin; concurrent chemoradiation; consolidation; docetaxel; elderly; etoposide; locally advanced; non-small-cell lung cancer; stage III; toxicity

Document Type: Research article

DOI: http://dx.doi.org/10.2217/ahe.12.14

Publication date: 2012-04-01

More about this publication?

• Aging Health leading coverage of current and emerging topics relating to the safe and effective management of therapy in the elderly, all subject to rigorous peer review. The journal focuses on the most important advances and highlights their relevance in the clinical setting. The journal has been designed to deliver essential concise information in an easily assimilable format - vital for the increasingly time-constrained professional.
• Editorial Board
• Information for Authors
• Submit a Paper
• Subscribe to this Title
• Information for Advertisers
• Terms & Conditions
• Information for Librarians
• E-Access Trials
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General) ,  Nursing
• By this author: Westeel, Virginie ;  Quoix, Elisabeth ;  Baudrin, Laurence ;  Milleron, Bernard

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers